# University of Michigan

> University of Michigan is a VC fund backing Biotechnology and Software. See 24 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Ann Arbor, United States
- Total investments: 24
- Last investment: Mar 2026
- Lead investor: 4%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/edu/university-of-michigan-18633
- X (Twitter): https://twitter.com/UMich
- Website: https://www.umich.edu/
- Facebook: http://www.facebook.com/universityofmichigan

University of Michigan is a VC fund in Ann Arbor focused on Biotechnology and Software. The University of Michigan’s programs consistently places high in national rankings. Especially renowned are the Stephen Ross School of Business, the College of Engineering, The Law and Medical Schools, and the Musical Theatre program. There is also a strong film presence in Ann Arbor, with many major motion pictures being shot there and the annualAnn Arbor Film Festival, which brings in filmmakers from all over the world.

## Contacts

5 contacts available for University of Michigan. Shizune tracks 23 team members at University of Michigan. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/university-of-michigan?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 5 | 21% |
| Software | 4 | 17% |
| Medical | 2 | 8% |
| Health Care | 2 | 8% |
| Life Science | 2 | 8% |

33 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Grant | 3 | 13% |
| Seed | 2 | 8% |
| Pre-Seed | 2 | 8% |
| Series B | 2 | 8% |
| Series C | 2 | 8% |

8 stages tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Alan Taub | Professor of Materials Science and Engineering | 0 | https://shizune.co/investors/profile/alan-taub |
| Brett Bilbrey | National Advisory Council Member | 0 | https://shizune.co/investors/profile/brett-bilbrey |
| David Ginsburg | Professor of Internal Medicine and Human Genetics | 0 | https://shizune.co/investors/profile/david-ginsburg-2 |
| David Olson | Mentor-In-Residence | 1 | https://shizune.co/investors/profile/david-olson |
| Henry Pollack | Professor | 0 | https://shizune.co/investors/profile/henry-pollack |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Sygaldry Technologies | Sygaldry Technologies is a tech company building quantum-accelerated AI servers to exponentially speed up AI training and inference. | $105M | Series A | Mar 01, 2026 |  |
| Atomic Industries | Atomic Industries is a computational manufacturing company building an AI-powered tool and die maker. | $25M | Series A | Jun 26, 2025 |  |
| Rescale | Rescale is a cloud simulation platform that enables research scientists and engineers to build, compute, analyze, and scale simulations.The high-performance computing cloud platform delivers intelligent computing for digital R&D and enables more than 300 customers from startups to Fortune 50 enterprises to accelerate design cycles and time tomarket. Rescale gives research scientists and engineers the ability to run their simulation and artificial intelligence workloads on the cloud provider of their choice, using specialized hardware architectures and software templates optimized for their use cases, without any set-up or maintenance. Investors such as Initialized Capital, Keen Venture Partners, SineWave Ventures, Data Collective, ITV Ventures, Jump Capital, and M12 (formerly Microsoft Ventures), as well as Mitsubishi UFJ Capital, Quiet Capital, Streamlined Ventures, Translink Capital, Two Roads Group, Y Combinator, Hitachi Ventures, Nautilus Venture Partners, NVIDIA, Republic Labs, and Samsung Catalyst Fund backs Rescale.In 2011, Joris Poort and Adam McKenzie headquartered the company in San Francisco, California. | $115M | Series D | Apr 07, 2025 |  |
| Infinium | Infinium is an electrofuels provider that creates synthetic fuels from renewable energy and waste carbon dioxide. Its electrofuels can be utilized in existing transportation systems, significantly lowering carbon emissions compared to traditional fossil fuels. Additionally, Infinium's solutions offer a lower carbon alternative for variouschemical processes, including plastics production. |  | Series C | Jan 16, 2025 |  |
| Stoke Space | Stoke Space develops the Nova rocket, a fully reusable launch vehicle designed to provide affordable access to and from Earth's orbit. The vehicle features a reusable upper stage that enables on-demand access to any orbit for cargo, logistics, and asset operations. Stoke Space operates vertically integrated design and manufacturing to buildand rapidly iterate on its rocket engines and structures. | $260M | Series C | Jan 15, 2025 |  |
| X-energy | X-Energy is a nuclear reactor and fuel design engineering company that develops Generation IV, high-temperature gas-cooled small modular reactors (SMRs) together with proprietary TRISO-X particle fuel. Their flagship reactor, the Xe-100, delivers about 80 MWe per unit and can be scaled in modular “packs” to reach higher output. X-Energy also buildsits own TRISO-X fuel to maintain supply control and quality. In addition, the company operates a plant support center to provide fleet monitoring, maintenance planning, training, and diagnostics for its reactor customers. | $700M | Series C | Oct 16, 2024 |  |
| Stoke Space | Stoke Space develops the Nova rocket, a fully reusable launch vehicle designed to provide affordable access to and from Earth's orbit. The vehicle features a reusable upper stage that enables on-demand access to any orbit for cargo, logistics, and asset operations. Stoke Space operates vertically integrated design and manufacturing to buildand rapidly iterate on its rocket engines and structures. | $100M | Series B | Oct 05, 2023 |  |
| ModernVivo | New drugs fail in human clinical trials 90% of the time. These failures can be traced directly back to the consistent inability of preclinical animal studies to predict clinical success. Yet the design process for preclinical animal studies has remained largely unchanged for decades; scientists read a tiny fraction of published literature and writetheir experimental protocols in 2-4 weeks. This time-consuming, tedious process is not only a major pain point for in-vivo scientists but leads to substantial experimental design flaws, resulting in unreliable data with which billion-dollar decisions are made. Scientists we’ve spoken to repeatedly express their struggle with the overwhelming amount of preclinical information they need to sift through in order to design experiments. At ModernVivo, we are revolutionizing this antiquated process by equipping scientists with tools that enable them to write in-vivo protocols more effectively. Our technology empowers scientists to streamline their work, accelerating drug development timelines. | $100K | Convertible Note | Sep 27, 2023 |  |
| ModernVivo | New drugs fail in human clinical trials 90% of the time. These failures can be traced directly back to the consistent inability of preclinical animal studies to predict clinical success. Yet the design process for preclinical animal studies has remained largely unchanged for decades; scientists read a tiny fraction of published literature and writetheir experimental protocols in 2-4 weeks. This time-consuming, tedious process is not only a major pain point for in-vivo scientists but leads to substantial experimental design flaws, resulting in unreliable data with which billion-dollar decisions are made. Scientists we’ve spoken to repeatedly express their struggle with the overwhelming amount of preclinical information they need to sift through in order to design experiments. At ModernVivo, we are revolutionizing this antiquated process by equipping scientists with tools that enable them to write in-vivo protocols more effectively. Our technology empowers scientists to streamline their work, accelerating drug development timelines. | $5K | Grant | Nov 01, 2022 |  |
| ModernVivo | New drugs fail in human clinical trials 90% of the time. These failures can be traced directly back to the consistent inability of preclinical animal studies to predict clinical success. Yet the design process for preclinical animal studies has remained largely unchanged for decades; scientists read a tiny fraction of published literature and writetheir experimental protocols in 2-4 weeks. This time-consuming, tedious process is not only a major pain point for in-vivo scientists but leads to substantial experimental design flaws, resulting in unreliable data with which billion-dollar decisions are made. Scientists we’ve spoken to repeatedly express their struggle with the overwhelming amount of preclinical information they need to sift through in order to design experiments. At ModernVivo, we are revolutionizing this antiquated process by equipping scientists with tools that enable them to write in-vivo protocols more effectively. Our technology empowers scientists to streamline their work, accelerating drug development timelines. | $10K | Grant | Oct 05, 2022 |  |

10 of 24 investments shown.

## Co-investors
- [Y Combinator](https://shizune.co/investors/profile/y-combinator) — VC Fund, 6 deals together
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund, 2 deals together
- [Artiman Ventures](https://shizune.co/investors/profile/artiman-ventures) — VC Fund, 2 deals together
- [Breakthrough Energy Ventures](https://shizune.co/investors/profile/breakthrough-energy-ventures) — VC Fund, 2 deals together
- [CBC Capital](https://shizune.co/investors/profile/cbc-capital) — VC Fund, 2 deals together
- [Industrious Ventures](https://shizune.co/investors/profile/industrious-ventures) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Scottish Enterprise](https://shizune.co/investors/profile/scottish-enterprise) — VC Fund
- [Foundation for Innovation and Technology (FIT)](https://shizune.co/investors/profile/foundation-pour-l-innovation-technologique) — VC Fund
- [Business Finland](https://shizune.co/investors/profile/tekes) — VC Fund

## FAQ

### What does University of Michigan invest in?

University of Michigan invests primarily in Biotechnology, Software and Medical startups, most often at Grant and Seed stage. Most of the 24 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact University of Michigan?

Public channels for University of Michigan include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at University of Michigan?

The team at University of Michigan includes Alan Taub (Professor of Materials Science and Engineering), Brett Bilbrey (National Advisory Council Member) and David Ginsburg (Professor of Internal Medicine and Human Genetics), among 23 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co